- PsychiatryAfter an undergraduate degree at Duke University, Dr. Friedman attended medical school at the University of Arizona, in his hometown of Tucson. He trained in Adult Psychiatry beginning in 1998 at the University of Miami. He followed that by a Residency in Child and Adolescent Psychiatry at NYU from 2001 to 2003, where he served as Chief Resident. In 2010, he completed training in neuromodulation for treatment of depression and other conditions with rTMS.
- MRITMS is the first depression treatment of its kind to be approved by the U.S. Food and Drug Administration (October 2008). The treatment, which is far safer and more convenient than electro-shock treatment (ECT), is clinically proven for the treatment of major depression in adults who have failed to achieve satisfactory improvement from antidepressant medication. This innovative treatment consists of focused, gentle magnetic stimulation (using a small MRI magnet) for thirty 40-minute sessions over 4-6 weeks, without use of sedation. Once inside the brain, the magnetic pulses induce a mild electrical current to flow, which cannot be felt by the patient, but which causes the brain cells to become active and are thought to lead to the release of neurotransmitters such as serotonin, norepinephrine and dopamine. Patients sit comfortably, watching TV while awake, in a recliner chair during each session. After treatment, patients can drive and resume normal activity.